France Asthma & COPD Therapeutics Market Report 2022 to 2030

France Asthma and COPD Therapeutics Market Analysis

$ 3999

The France Asthma and COPD Therapeutics Market was valued at US $0.92 Bn in 2022, and is predicted to grow at (CAGR) of 4.20% from 2023 to 2030, to US $1.28 Bn by 2030. The key drivers of this industry include the rise in the prevalence of COPD and asthma, unmet medical needs, technological advancements, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Tetherex, Novartis, Sulfateq, Verona, and Boehringer Ingelheim, among others.

ID: IN10FRPH433 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Riddhi Solanki

Buy Now

France Asthma and COPD Therapeutics Market Analysis: Executive Summary

The France Asthma and COPD Therapeutics Market is at around US $0.92 Bn in 2022 and is projected to reach US $1.28 Bn in 2030, exhibiting a CAGR of 4.20% during the forecast period.

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are chronic respiratory conditions that affect the airways, leading to breathing difficulties. Asthma is characterized by inflammation and narrowing of the airways, often triggered by allergens, irritants, or physical activity. Common symptoms include wheezing, shortness of breath, chest tightness, and coughing, with risk factors such as a family history and respiratory infections. COPD includes chronic bronchitis and emphysema, causing obstructed airways, with smoking identified as a primary risk factor. Observable COPD symptoms include a persistent cough, increased mucus production, and fatigue. Treatment for both asthma and COPD involves the use of bronchodilators to alleviate airway constriction and anti-inflammatory medications to address inflammation. Pharmaceuticals from companies like GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim are commonly prescribed for these conditions. Ongoing advancements in therapeutic approaches for asthma and COPD focus on innovative anti-inflammatory agents, bronchodilators, and targeted therapies.

Approximately 7% of the population is impacted by COPD, while the prevalence of asthma varies from around 6.5% to 9.5% across adults and children in France. These figures are strongly associated with elevated rates of smoking, air pollution, and occupational exposures within the population. The primary factors driving the market are the rising prevalence of asthma and COPD, technological advancements, unmet demand, and others. However, high costs of advanced treatment, limited access to healthcare, and reimbursement challenges are a few factors that limit the market's potential.

Market Dynamics

Market Growth Drivers

Rising disease prevalence: France exhibits a notable prevalence of both COPD and Asthma, with around 3.5-7% of adults experiencing COPD and approximately 6.4% of adults and 9.5% of children suffering from Asthma. Anticipated factors contributing to a potential increase in these numbers include an increasing aging population, heightened urbanization, and elevated exposure to environmental triggers like air pollution. This translates into a huge patient pool that requires regular treatment, leading to market growth.

Technological advancements: Pharmaceutical firms are currently engaged in the development of advanced treatments, such as biologics and combination inhalers, providing more precise and efficient options for various disease phenotypes. Enhancements in delivery devices, including nebulizers, dry powder inhalers, and smart inhalers, are boosting the efficiency of medication administration and promoting better adherence among patients in France.

Unmet medical need: Although current treatments effectively address symptoms, they do not provide a cure for COPD or ensure complete prevention of asthma attacks. The pursuit of novel therapies with disease-modifying or curative potential is motivated by this unmet need in research.

Supportive government policies: The initiatives undertaken by the French government to enhance the management of chronic diseases are expected to positively impact the market for asthma and COPD therapeutics. These efforts focus on encouraging early diagnosis, ensuring access to treatment, and providing patient education.

Market Restraints

High Cost of Treatment: Costly inhalers and delivery systems, such as inhalers and nebulizers, pose a financial challenge for a substantial portion of the population, especially those lacking sufficient health insurance. This financial barrier may result in non-adherence to medication regimens and poor treatment outcomes. Additionally, newer biologic therapies, although highly effective, often carry substantial price tags, placing further strain on healthcare budgets and limiting affordability for patients.

Limited access to healthcare: Especially in rural areas, individuals may encounter challenges in reaching healthcare providers and specialists, resulting in delayed diagnosis and treatment. Extended waiting periods for appointments and a lack of convenient transportation options can additionally hinder timely access to healthcare.

Reimbursement challenges: The intricacies of the French healthcare system and limitations in insurance coverage can impose restrictions on accessing specific medications and therapies. Lengthy and bureaucratic processes for approving new drugs can also postpone their availability to patients.

Notable Updates

March 2023, Sanofi's asthma drug Dupixent met all targets in a Phase III trial to treat COPD (smoker’s lung), potentially adding billions to the French therapeutics market.

Healthcare Policies and Regulatory Landscape

France's healthcare policy and regulatory framework are managed by the Ministry of Solidarity and Health, which serves as the primary governing body. This ministry is tasked with formulating and executing national health policies, ensuring the effectiveness and availability of healthcare services, and overseeing public health initiatives. The French National Authority for the Safety of Medicines and Medical Devices (ANSM) holds the primary responsibility for regulating these products, ensuring adherence to high standards of safety, efficacy, and quality.

Securing a medical license in France entails a multifaceted process. Aspiring healthcare professionals, including doctors, nurses, and other practitioners, are required to complete their education at accredited institutions. The regulatory bodies ensure that healthcare professionals meet the necessary qualifications and adhere to ethical standards.

France's comprehensive healthcare system underscores the importance of universal access to quality care, placing a strong emphasis on preventative measures and public health initiatives.

Competitive Landscape

Key Players

GlaxoSmithKline
AstraZeneca
Boehringer-Ingelheim Pharmaceuticals
Novartis
Sulfateq BV
Abbott Laboratories
Merck
Synairgen
Tetherex Pharmaceuticals
Verona Pharma

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Asthma and COPD Therapeutics Market Segmentation

By Disease Type

Asthma
COPD

By Medication Class

Combination drugs
Short Acting Beta Agonists (SABA)
Long Acting Beta Agonists (LABA)
Leukotriene Antagonists (LTA)
Anticholinergics
Others

By Delivery Device

Metered dose inhalers (MDI)
Dry Powder inhalers (DPI)
Nebulizers

By Route of Administration

Inhaled
Oral
Others

By End User

Asthma Patients
COPD Patients

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.